Osteoimmunology of Spondyloarthritis

Fassio, Angelo; Atzeni, Fabiola; Rossini, Maurizio; D’Amico, Valeria; Cantatore, Francesco; Chimenti, Maria Sole; Crotti, Chiara; Frediani, Bruno; Giusti, Andrea; Peluso, Giusy; Rovera, Guido; Scolieri, Palma; Raimondo, Vincenzo; Gatti, Davide; ,

doi:10.3390/ijms241914924

Cited by 3 publications

(4 citation statements)

References 213 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enthesitis is currently regarded as a fundamental pathological process in the development of SpA and a key finding of musculoskeletal inflammation in diseases from the SpA spectrum, such as PsA. This condition leads to significant inflammation, bone destruction, and pathological bone proliferation, highlighting its critical role in the progression and severity of these diseases [ 23 ].…”

Section: Ultrasonographic Assessment Of Psoriatic Arthritismentioning

confidence: 99%

“…Recent data on osteoimmunology highlight that bone destruction and bone neoformation are direct consequences of enthesitis, a condition recognized as one of the fundamental pathological processes in the development of SpA. This understanding underscores the critical role of enthesitis in the progression of SpA and its impact on bone integrity and remodeling [ 23 ].…”

Section: Ultrasonographic Assessment Of Psoriatic Arthritismentioning

confidence: 99%

“…Table 1. Inflammatory and damage domains from the OMERACT (Outcome Measures in Rheumatology) enthesitis definition [23].…”

Section: Enthesitismentioning

confidence: 99%

“…Furthermore, major cytokines such as IL-17, TNFα, IL-23, and IL-6 are deeply involved in the pathogenesis and amplification of inflammation within the SpA disease spectrum. These cytokines interact with the bone microenvironment, contributing to both the erosive and proliferative bone changes that characterize the disease [23]. [48] and OMERACT [45] definitions.…”

Section: Bone Changesmentioning

confidence: 99%

See 3 more Smart Citations

Ultrasonographic Insights into Peripheral Psoriatic Arthritis: Updates in Diagnosis and Monitoring

Bonfiglioli,

Lopes,

Figueiredo

et al. 2024

JPM

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis, characterized by heterogeneous clinical manifestations and variable disease progression. Ultrasonography has emerged as a valuable tool in the diagnosis and monitoring of PsA, providing real-time visualization of joint and soft tissue abnormalities. This review highlights recent advancements in ultrasonographic techniques for the assessment of PsA, including the identification of typical features, the role of power Doppler imaging in detecting active inflammation, and the potential of ultrasound for guiding treatment decisions. Additionally, we discuss the utility of ultrasound in assessing treatment response and monitoring disease progression in patients with PsA, with a focus on novel imaging modalities. By elucidating the evolving role of ultrasonography in PsA management, this article aims to enhance clinicians’ understanding of its utility in facilitating early diagnosis, optimizing treatment strategies, and improving patient outcomes.

show abstract

Section: Ultrasonographic Assessment Of Psoriatic Arthritismentioning

confidence: 99%

Section: Ultrasonographic Assessment Of Psoriatic Arthritismentioning

confidence: 99%

“…Table 1. Inflammatory and damage domains from the OMERACT (Outcome Measures in Rheumatology) enthesitis definition [23].…”

Section: Enthesitismentioning

confidence: 99%

Section: Bone Changesmentioning

confidence: 99%

See 2 more Smart Citations

Ultrasonographic Insights into Peripheral Psoriatic Arthritis: Updates in Diagnosis and Monitoring

Bonfiglioli,

Lopes,

Figueiredo

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Ramonda,

Lorenzin,

Chimenti

et al. 2024

Arthritis Res Ther

View full text Add to dashboard Cite

Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients. Methods Consecutive PsA patients receiving secukinumab were followed prospectively in Italian centers between 2016 and 2023. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were recorded. Treatment response was evaluated at 6 and 12 months after initiation, and every year up to 48 months (T48). DRR was assessed according to clinical and demographic features, comorbidities and bDMARDs line. Adverse events (AE) were recorded. Results Six hundred eighty-five patients [42.5% male] were enrolled; 32.9% naïve received secukinumab; 74.2% had ≥ 1 comorbidity. Overall, secukinumab yielded improved outcomes at T48: naïve maintained lower disease activity vs. non-naïve [DAPSA 4.0 (1.4–8.1) vs. 6.0 (2.2–10.4);p = 0.04]; 76.9% naïve and 66.2% non-naïve achieved MDA; MDA no comorbidities vs. 1–3 comorbidities 78.8% vs. 73.3% (p < 0.05), and MDA no comorbidities vs. > 3 comorbidities 78.8% vs. 48.7% (p < 0.001). DAPSA-REM and DAPSA-LDA rates were higher in naïve patients, albeit similar between those without comorbidities vs. 1–3 comorbidities, and slightly lower in those with > 3 comorbidities. Treatment was discontinued in 233 patients due to loss of effectiveness, and in 41 due to AE. The overall DRR at T48 was 66%, with differences according to bDMARDs line (p < 0.001), use of combined csDMARDs (p = 0.016), BMI (p = 0.037) and mono/oligoarthritis vs. polyarthritis (p = 0.012). Conclusions Secukinumab proved safe and effective, and patients achieved sustained remission with a notable drug retention rate at 4 years.

show abstract

Descending Aorta Calcinosis and Hypertension in Patients with Radiographic Axial Spondyloarthritis

Aksonova,

Kirzhner,

Smarovoz

2024

ujcvs

View full text Add to dashboard Cite

This article is the result of our own clinical observations and a literature search on the development of aortic calcification and hypertension syndrome in patients with axial spondyloarthritis, as well as the clinical significance of the combination of these pathologies and management thereof. The aim. To increase the awareness of practicing doctors regarding the possible association of aortic calcification and hypertension in patients with axial spondyloarthritis, their diagnosis and possible development mechanisms. Materials and methods. For this article we described two patients with axial spondyloarthritis, calcinosis of descending aorta and high blood pressure and conducted a case-based review of related literature. Results. The article presents the results of studies, where authors tried to explain possible mechanisms of development of aortic calcification and hypertension in patients with axial spondyloarthritis. Despite the fact that the data of these studies are scattered and researchers have not yet reached a certain consensus, the available results allow us to believe that patients with axial spondyloarthritis are at increased risk for the development of aortic calcification and hypertension syndrome. Given the possible consequences of these lesions, this cohort of patients requires increased attention from clinicians of various profiles. Conclusions. Aortic calcinosis can develop in patients with axial spondyloarthritis at its various stages, and also be one of the reasons for the development of high hypertension in such patients. We consider it expedient to conduct a routine examination of the aorta in patients with radiographic axial spondyloarthritis in case of detection of hypertension in them, because this group of patients has a pathophysiological basis for the calcification of vessels of the elastic type, which is given above. This will make it possible to correctly assess the patient’s cardiovascular risks, to draw up more correct plan for their long-term management by a cardiologist in cooperation with a rheumatologist and a cardiac surgeon, as well as to choose more effective therapy for blood pressure correction.

show abstract

Osteoimmunology of Spondyloarthritis

Cited by 3 publications

References 213 publications

Ultrasonographic Insights into Peripheral Psoriatic Arthritis: Updates in Diagnosis and Monitoring

Ultrasonographic Insights into Peripheral Psoriatic Arthritis: Updates in Diagnosis and Monitoring

Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Descending Aorta Calcinosis and Hypertension in Patients with Radiographic Axial Spondyloarthritis

Contact Info

Product

Resources

About